108
Participants
Start Date
June 30, 2010
Primary Completion Date
January 31, 2013
Study Completion Date
January 31, 2013
Intravenous Carbamazepine (IV CBZ)
10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
Langone Medical Center NYU Comprehensive Epilepsy Center, New York
Columbia University Medical Center: Dept of Neurology, New York
Montefiore Medicical Center, The Bronx
SUNY Upstate Medical University, Syracuse
University of Rochester, Rochester
Temple University Health systems, Philadelphia
Mid-Atlantic Epilepsy and Sleep Center, Bethesda
University of Virginia, Charlottesville
Wake Forest University Health Sciences, Winston-Salem
Medical University of South Carolina, Charleston
University of South Florida, Tampa
Cleveland Clinic, Cleveland
University of Minnesota & Prism Research, Saint Paul
Central DuPage Hospital, Winfield
University of Illinois at Chicago, Chicago
Southern illinois University School of Medicine, Springfield
The Comprehensive Epilepsy Care Center for Children and Adults, Chesterfield
Via Christi Epilepsy Center, Wichita
Louisiana Research Associates, New Orleans
Ochsner Clinic Foundation, New Orleans
Leonard J. Chabert Medical Center, Houma
Clinical Trials Incorporated, Little Rock
Neurological Clinic of Texas, P.A., Dallas
Scott & White Memorial Hospital, Temple
Denver Health and Hospital Authority, Denver
Mayo Clinic Arizona, Phoenix
Collaborative Neuroscience Network, Inc., Torrance
Beth Israel Deaconess Medical Center, Boston
VCU Medical Center, Richmond
Lead Sponsor
Collaborators (2)
Ligand Pharmaceuticals
INDUSTRY
ICON Clinical Research
INDUSTRY
Quintiles, Inc.
INDUSTRY
Lundbeck LLC
INDUSTRY